The cost-effectiveness of two strategies for vaccinating U.S. veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses

American Journal of the Medical Sciences

Volumn 333, Issue 1, 2007, Pages 26-34

  Jakiche, Rita ^a,e   Borrego, Matthew E ^a   Raisch, Dennis W ^a,b   Gupchup, Gireesh V ^c   Pai, Manjunath A ^a   Jakiche, Antoine ^d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b Center for Scientific Affairs   (Mexico)

^c SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^d VA Medical Center   (United States)

^e Albuquerque VA Cooperative Study   (United States)

Author keywords

Cost effectiveness; Hepatitis A vaccine; Hepatitis B vaccine; Hepatitis C virus

Indexed keywords

ENGERIX B 20; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS VACCINE; UNCLASSIFIED DRUG;

ADULT; BLOOD EXAMINATION; COST; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FEMALE; HEALTH CARE SYSTEM; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LITERATURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROBABILITY; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; UNITED STATES; VACCINATION; VETERAN; VIRUS IMMUNITY; VIRUS INFECTION;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HEPACIVIRUS; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; VACCINATION;

EID: 33846241305     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200701000-00004     Document Type: Review

References (34)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(5 Suppl 1):S30-4.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35-46.
4. Austin GE, Jensen B, Leete J, et al. Prevalence of hepatitis C virus seropositivity among hospitalized US veterans. Am J Med Sci 2000;319:353-9.
5. Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001;34:1200-5.
6. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000;95:740-7.
7. Roselle GA, Danko LH, Kralovic SM, et al. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med 2002;167:756-9.
8. Sloan KL, Straits-Troster KA, Dominitz JA, et al. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. J Clin Gastroenterol 2004;38:279-84.
9. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989;110:838-9.
10. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-5.
11. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
12. Willner IR, Uhl MD, Howard SC, et al. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998;128:111-4.
13. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.
14. Chiba T, Matsuzaki Y, Abei M, et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996;91:1195-203.
15. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
16. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36(5 Suppl 1):S3-20.
17. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
18. Lee SD, Chan CY, Yu MI, et al. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999;59:463-8.
19. Jakiche R, Dwivedi P, Borrego ME, et al. US Veterans with hepatitis C have a high prevalence of immunity to hepatitis A and hepatitis B, and a high prevalence of decompensated liver disease. Am J Gastroenterol 2004;99:84 Abstract.
20. Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001;19:4710-9.
21. Arguedas MR, Heudebert GR, Fallon MB, et al. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002;97:721-8.
22. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002;97:427-34.
23. Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000;31:834-9.
24. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999;94:1601-4.
25. De Maria N, Idilman R, Colantoni A, et al. Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection. Hepatology 2000;32:444-5.
26. Kamel M, el Manialawi M, Miller FD. Recombinant hepatitis B vaccine immunogenicity in presence of hepatitis C virus seropositivity. Lancet 1994;343:552.
27. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999;318:304-7.
28. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000;14 Suppl B:59B-62B.
29. Asboe D, Rice P, de Ruiter A, et al. Hepatitis B vaccination schedules in genitourinary medicine clinics. Genitourin Med 1996;72:210-2.
30. Quaglio G, Talamini G, Lugoboni F, et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction 2002;97:985-92.
31. Sellors J, Pickard L, Mahony JB, et al. Understanding and enhancing compliance with the second dose of hepatitis B vaccine: a cohort analysis and a randomized controlled trial. CMAJ 1997;157:143-8.
32. Bloom BS, Hillman AL, Fendrick AM, et al. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298-306.
33. Bayas JM, Gonzalez A, Vilella A, et al. Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries. Epidemiol Infect 2001;127:347-51.
34. Polesky HF, Hanson MR. Comparison of viral hepatitis marker test methods based on AABB-CAP survey data. Am J Clin Pathol 1981;76(4 Suppl):521-4.